YM155 is a potent IAP (inhibitor of apoptosis proteins) inhibitor for Survivin. YM155 is currently in Phase II clinical trial in advanced non-small cell lung carcinoma. YM155 is dissolved in DMSO and added to cells for 48 hours. The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice.
Formulation | Dissolved and diluted in saline immediately before administration
---|---
Doses | 5 mg/kg
Administration | Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump

References

Customer Reviews

Data from [PLoS ONE, 2011, 6, e21980]
YM155 purchased from Selleck
YM155 sensitizes ABT-263-induced apoptosis in HCC cells. A. LH86 and B. Huh7 cells were untreated or treated with ABT-263(1 μM), YM-155(1 μM) or combination of ABT-263(1 μM) and YM-155(1 μM) for up to 6 h. Then apoptotic cells were assessed as in Figure 2A and 2B (representative apoptotic cells were marked with white arrows). C. LH86 and D. Huh7 cells were untreated or treated with ABT-263(1 μM), YM-155(1 μM) or combination of ABT-263(1 μM) and YM-155(1 μM) for 6 h. Cells with apoptotic nuclei were counted to determine cell death ratio (*p<0.05, **p<0.05). E. LH86 cells and F. Huh7 cells were treated as indicated and

reference cell lysates were prepared and subjected to Western blotting. Apoptosis was evaluated through caspase 3 activation. b-actin was used as an equal protein loading control. G. LH86 cells grown in six-well plate were untreated (control) or treated with different conditions as indicated for 48 h. After rinsed with fresh culture medium for 3 times, cells were cultured for another two weeks. Cell colony formation assays were performed with crystal violet staining. H. colony number were counted to show combination treatment with ABT-263 and YM-155 resulted in reduction of clonogenesis (#p<0.05).

Data from [Basic Res Cardiol, 2011, 106(6), 1207-1220]
YM155 purchased from Selleck
Induction of cardiomyocytes apoptosis by survivin inhibitor in vivo. After YM155 was administered (5 mg/kg/day) for 5 days, the rats were exposed to a 40% TBSA burn (burn injury) or 25C water (sham) and killed 6 h after burn injury. The frozen sections of the ventricular tissues or whole cell lysates were prepared. Apoptotic staining was performed using the TUNEL method and immunostained using a-sarcomeric actin. The survivin and cleaved caspase-3 levels were measured by Western blot analysis. a Representative blots of survivin and cleaved caspase-3. b The statistical analysis of the relative proteins. c Figures are representative of two independent TUNEL experiments. Green fluorescence represents apoptotic cells, whereas red stain indicates staining for a-sarcomeric actin specific for cardiac myocytes. d Bar graph summarizes the counted apoptotic cells.

PLEASE KEEP THE PRODUCT UNDER -20°C FOR LONG-TERM STORAGE.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality, but save your shipping charges by using the most economical storage conditions for an overnight shipment. Upon receipt of the product, follow the storage recommendations on the product datasheet.